(Press-News.org) A new study published in Addiction has identified genetic factors that influence both a person’s risk of developing an addiction and their educational attainment. Researchers found that some genetic variants affect both traits in opposite directions, meaning that a higher genetic risk for addiction is associated with an increased likelihood of lower educational attainment.
Lead author Dr. Judit Cabana-Domínguez from the Vall d’Hebron Research Institute (VHIR) explains: “We have long known that substance use problems and school difficulties often appear together and make each other worse. Our research shows that part of this connection is explained by shared genetic factors.”
The research team recruited over 1,400 participants with substance use disorders involving cocaine, opiates, cannabis and/or sedatives. Using a Genome-Wide Association Study (GWAS), they identified a subset of genetic variants that both increase the risk of addiction and are associated with lower educational attainment. This group of genetic variants is linked not only to substance use disorders but also to poorer health and socioeconomic outcomes. Together, these findings suggest a genetic connection between addiction and lower educational attainment, though they do not provide enough evidence to determine whether one causes the other.
According to Dr. Judit Cabana-Domínguez, “Although we found consistent evidence of shared genetic variants influencing both risk of addiction and risk of low educational attainment, our study cannot determine whether low educational attainment increases the risk for addiction, whether addiction leads to school difficulties, or whether both are true. Although much research remains, our findings suggest that promoting higher educational attainment may help health systems to improve and implement prevention strategies for substance use disorders.”
-- Ends –
For editors:
This Open Access paper is available on the Wiley Online Library after the embargo has lifted (https://onlinelibrary.wiley.com/doi/10.1111/add.70254) or you may request an early copy from Jean O’Reilly, Editorial Manager, Addiction, jean@addictionjournal.org.
To speak with lead author Dr. Judit Cabana-Domínguez, please contact her at the Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona by email (comunica@vhir.org) or telephone (+34 934894162).
Full citation for article: Cabana-Domínguez J, Vilar-Ribó L, Soler Artigas M, Alemany S, Llonga N, Carabí-Gassol P, Zubizarreta-Arruti U, Macias-Chimborazoa V, Grau-López L, Daigre C, Ros-Cucurull E, Palma-Alvarez RF, Ortega-Hernández G, Fernàndez-Castillo N, Cormand B, Ramos-Quiroga JA, and Ribasés M. Exploring the genetic overlap between substance use disorder and educational attainment. Addiction. 2025. DOI: 10.1111/add.70254.
Primary funding: This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Network Center for Biomedical Research (CIBER) to J.C.D.; the European Regional Development Fund (ERDF); the ECNP Network ‘ADHD across the Lifespan’; “la Marató de TV3” (202228-30 and 202228-31), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN). “Plan Nacional Sobre Drogas” of the Spanish Ministry of Health (PNSD-2020I042) to NF-C, the Spanish “Ministerio de Ciencia, Innovación y Universidades” (PID2021-127776OB-I00 and PID2024-158634OB-I100) and AGAUR-Generalitat de Catalunya (2021-SGR-01093) to NF-C and BC; “la Marató de TV3” (202218-31) and ICREA Academia 2021 to BC.
Declaration of interests: J.A.R.Q was on the speakers’ bureau and/or acted as consultant for Biogen, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Rubió, Uriach, Technofarma and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Psychiatry chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen- Cilag, Shire, Oryzon, Roche, Psious, and Rubió. R.F.P.A has received speaker honorariums from Angelini, Casen Recordati, Exeltis, Lundbeck, MSD, Mundipharma, Rubió, Servier, and Takeda. G.O-H has received speaker honorariums from Casen Recordati, Lundbeck and Rubió. ERC has received financial compensation for her participation as a speaker and/or board member from Angelini, Casen Recordati, Esteve, Exeltis, Idorsia, Janssen, Juste, Lilly, Lundbeck, Otsuka, Pfizer, Rovi, Servier. She has received research grants from Acadia, Boehringer Ingelheim, Eisai, HMNC Holding GmbH, Janssen, Lundbeck, Novartis, Otsuka, Roche. All other authors declare no biomedical financial interests or conflicts of interest.
Addiction (www.addictionjournal.org) is a monthly international scientific journal publishing peer-reviewed research reports on alcohol, substances, tobacco, gambling, editorials, and other debate pieces. Owned by the Society for the Study of Addiction, it has been in continuous publication since 1884.
END
New research identifies shared genetic factors between addiction and educational attainment
2025-12-11
ELSE PRESS RELEASES FROM THIS DATE:
Epilepsy can lead to earlier deaths in people with intellectual disabilities, study shows
2025-12-11
A combination of missed prevention opportunities and health inequalities can result in the early deaths of people living with epilepsy and intellectual disabilities, a study has shown.
Around 1.2million people in England have some form of intellectual disability, with epilepsy estimated to impact 20-25% of them – up to 300,000 people – compared to just 1% of the general population.
However, until now there has been no national-level population-based evidence on the risks and protective factors specifically contributing to epilepsy-related deaths in people with intellectual disability.
This new research aims to ...
Global study suggests the underlying problems of ECT patients are often ignored
2025-12-11
A major international survey of people receiving electroconvulsive therapy (ECT) has found that most patients are not asked about the childhood adversities or recent life stressors that they believe caused their difficulties.
The survey findings, published in the International Journal of Mental Health Nursing, suggest that people are prescribed ECT, often against their will, without the underlying causes of their mental health problems being recognised and addressed by other therapeutic means.
The ...
Mapping ‘dark’ regions of the genome illuminates how cells respond to their environment
2025-12-10
Researchers at Duke University used CRISPR technologies to discover previously unannotated stretches of DNA in the ‘dark genome’ that are responsible for controlling how cells sense and respond to the mechanical properties of their local environment.
Understanding how these DNA sequences affect cellular identity and function could give researchers new therapeutic targets for illnesses that involve changes to mechanical properties of tissues, including fibrosis, cancer and stroke, as well as long-term issues such as neurodegeneration and even aging.
This work appears online on September 25 in the journal Science.
The ...
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
2025-12-10
Today at the San Antonio Breast Cancer Symposium (SABCS), researchers presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and Caris Life Sciences® (Caris) focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence (AI). The public-private partnership pairs ECOG-ACRIN’s extensive clinical trial expertise and biorepository resources with Caris’ comprehensive MI Cancer Seek® whole exome and whole transcriptome profiling, whole slide imaging, ...
Satellite data helps UNM researchers map massive rupture of 2025 Myanmar earthquake
2025-12-10
The March 28, 2025, Myanmar earthquake is giving scientists a rare look into how some of the world’s most dangerous fault systems behave, including California’s San Andreas Fault. Earthquakes are notoriously messy and complex, but this one struck along an unusually straight and geologically “mature” fault, creating near-ideal conditions for researchers to observe how the Earth releases energy during a major continental rupture.
An international team of researchers led by The University ...
Twisting Spins: Florida State University researchers explore chemical boundaries to create new magnetic material
2025-12-10
Florida State University researchers have created a new crystalline material with unusual magnetic patterns that could be used for breakthroughs in data storage and quantum technologies.
In a study published in the Journal of the American Chemical Society, the research team showed that when two materials with neighboring chemical compositions but different structure types are combined, they can form a new material that exhibits a third structure type with highly unusual magnetic properties.
Atoms in magnetic materials act as extremely small magnets, ...
Mayo Clinic researchers find new hope for toughest myeloma through off-the-shelf immunotherapy
2025-12-10
ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can generate deep and durable responses in extramedullary multiple myeloma — one of the most aggressive and treatment-resistant forms of the disease.
"We are seeing powerful responses in a disease that historically has resisted every therapy," says Shaji Kumar, M.D., a Mayo Clinic Comprehensive Cancer Center hematologist and senior author of the study. "By recruiting T cells ...
Cell-free DNA Could Detect Adverse Events from Immunotherapy
2025-12-10
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns Hopkins Kimmel Cancer Center have found.
In a Dec. 11 letter to the editor of the New England Journal of Medicine, the researchers described how they measured cell-free DNA to identify tissue damage to nine organs in a study involving 14 patients with solid tumors who received immune checkpoint inhibitor therapy, a treatment that helps boost the immune system’s ability to attack cancer. The test determined that the six patients in the cohort who had immune-related adverse events ...
American College of Cardiology announces Fuster Prevention Forum
2025-12-10
The American College of Cardiology is launching an early cardiovascular disease prevention education program to honor the contributions of Valentin Fuster, MD, PhD, MACC, and his lifelong commitment to establishing a culture of prevention in children. The Fuster Prevention Forum is an in-person educational course that will teach clinicians effective ways to educate children, parents and educators in their communities on nutrition, physical activity and emotional well-being.
“Valentin Fuster has a legacy of promoting heart healthy behaviors early ...
AAN issues new guideline for the management of functional seizures
2025-12-10
EMBARGOED FOR RELEASE UNTIL 4:00 P.M. ET, WEDNESDAY, DECEMBER 10, 2025
Highlights:
A new guideline by the American Academy of Neurology says psychological interventions are possibly effective in helping people achieve freedom from functional seizures.
Functional seizures, previously known as psychogenic nonepileptic seizures or non-epileptic attack disorder, can look or feel like seizures from epilepsy or fainting, but they have their own typical features.
The guideline says appropriate treatment may decrease the frequency of functional seizures, decrease anxiety and improve quality of life.
The guideline recommends that antiseizure ...